Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

Pediatric Blood and Cancer

Volumn 54, Issue 1, 2010, Pages 47-54

  Meany, Holly J ^a,b   Sackett, Dan L ^c   Maris, John M ^d   Ward, Yvona ^b   Krivoshik, Andrew ^e   Cohn, Susan L ^f   Steinberg, Seth M ^b   Balis, Frank M ^b   Fox, Elizabeth ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e ABBOTT LABORATORIES   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

ABT 751; Cytotoxicity; Neuroblastoma; Pediatric; Tubulin

Indexed keywords

COMBRETASTATIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; RETINOID; SULFORHODAMINE B; TUBULIN; VINCRISTINE; VINCRISTINE SULFATE; SULFONAMIDE; TUBULIN MODULATOR;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; BRAIN DISEASE; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DEHYDRATION; DEPOLYMERIZATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MICROTUBULE ASSEMBLY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROPATHIC PAIN; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POLYMERIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PROCESSING; QUALITY OF LIFE; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR RECURRENCE; WEIGHT REDUCTION; WESTERN BLOTTING; WHOLE BODY RADIATION; DISEASE FREE SURVIVAL; DRUG EFFECT; METABOLISM; PATHOLOGY; PILOT STUDY; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PILOT PROJECTS; PROGNOSIS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; TUBULIN; TUBULIN MODULATORS;

EID: 73349114644     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22267     Document Type: Article

References (30)

1. Iwamoto Y, Nisho K, Fukumoto H, et al. Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010 resistant cell lines. Jpn J Cancer Res 1998;89:954-962.
2. Nogales E. A structural view of microtubule dynamics. Cell Mol Life Sci 1999;56:133-142.
3. Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-3213.
4. Funahashi Y, Koyanagi N, Kitoh K. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Cancer Chemother Pharmacol 2001;47:179-184.
5. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994;54:1702-1706.
6. Owa T, Yoshino H, Okauchi T, et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 1999;42:3789-3799.
7. Morton CL, Favours EG, Mercer KS, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007;25:285-295.
8. Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-4887.
9. Fox E, Maris JM,Widemann BC, et al.Aphase I study ofABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008;14:1111-1115.
10. Fox E,Widemann BC, Maris JM, et al. The pharmacokinetics (PK) and pharmacodynamics (PD) of ABT-751 in children with recurrent neuroblastoma or other solid tumors. Proc ASCO 2007;25: Abstract #9557.
11. Fox E, Adamson PC, Hagey A, et al. Phase 1 trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma. Proc ASCO 2005;23:806. Abstract #8527.
12. Varni JW, Burwinkle TM, Katz ER, et al. The PedsQL in pediatric cancer: Reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer 2002;94:2090-2106.
13. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-766.
14. Perez RP, Godwin AK, Handel LM, et al. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 1993;29A:395-399.
15. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-1118.
16. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
17. Atienza JM, Zhu J, Wang X, et al. Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 2005;10:795-805.
18. Solly K, Wang X, Xu X, et al. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004;2:363-372.
19. Xing JZ, Zhu L, Jackson JA, et al. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 2005; 18:154-161.
20. Xiao C, Lachance B, Sunahara G, et al. Assessment of cytotoxicity using electric cell-substrate impedance sensing: Concentration and time response function approach. Anal Chem 2002;74:5748-5753.
21. Barra HS, Arce CA, Argarana CE. Posttranslational tyrosination/ detyrosination of tubulin. Mol Neurobiol 1988;2:133-153.
22. Maruta H, Greer K, Rosenbaum JL. The acetylation of alpha-tubulin and its relationship to the assembly and disassembly of microtubules. J Cell Biol 1986;103:571-579.
23. Kreis TE. Microtubules containing detyrosinated tubulin are less dynamic. EMBO J 1987;6:2597-2606.
24. Schulze E, Asai DJ, Bulinski JC, et al. Posttranslational modification and microtubule stability. J Cell Biol 1987;105:2167-2177.
25. Gershoni JM, Palade GE. Protein blotting: Principles and applications. Anal Biochem 1983;131:1-15.
26. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
27. Vachereau A. Luminescent immunodetection of western-blotted proteins from coomassie-stained polyacrylamide gel. Anal Biochem 1989;179:206-208.
28. Baschong W, Duerrenberger M, Mandinova A, et al. Three-dimensional visualization of cytoskeleton by confocal laser scanning microscopy. Methods Enzymol 1999;307:173-189.
29. Carlsson K. Three-dimensional specimen reconstruction by confocal microscopy and digital image processing. Bull Assoc Anat (Nancy) 1991;75:105-108.
30. Wright SJ, Schatten G. Confocal fluorescence microscopy and three-dimensional reconstruction. J Electron Microsc Tech 1991;18:2-10.